Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lb Pharmaceuticals (LBRX) Free Cash Flow (2024 - 2026)

Lb Pharmaceuticals' quarterly Free Cash Flow came in at -$23.3 million in Q1 2026, down 186.19% year-on-year from $27.1 million in Q1 2025, and down 28.57% quarter-over-quarter from -$18.1 million in Q4 2025.

Lb Pharmaceuticals has reported Free Cash Flow for 3 years, with the latest figure at -$23.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Free Cash Flow fell 186.19% year-over-year to -$23.3 million; the trailing twelve-month figure through Mar 2026 stood at -$49.6 million (changed N/A YoY), and the FY2025 full-year result was -$35.3 million, up 34.5% from the prior year.
  • Free Cash Flow for Q1 2026 stood at -$23.3 million, down from -$18.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$5.9 million in Q4 2024, with the low at -$23.3 million in Q1 2026.
  • Average Free Cash Flow over 3 years is -$13.9 million, with a median of -$13.1 million recorded in 2025.
  • Year-over-year, Free Cash Flow plunged 207.3% in 2025 and plunged 186.19% in 2026.
  • Tracing LBRX's Free Cash Flow over 3 years: stood at -$5.9 million in 2024, then sank by 207.3% to -$18.1 million in 2025, then fell by 28.57% to -$23.3 million in 2026.
  • The last three Free Cash Flow figures came in at -$23.3 million (Q1 2026), -$18.1 million (Q4 2025), and -$8.1 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -1.67 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 1.29 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 848.30 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 48.67 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - -23.32 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -23.32 Mn
Mar 31, 2026 -23.32 Mn
Dec 31, 2025 -18.14 Mn
Dec 31, 2025 -18.14 Mn
Mar 31, 2025 -8.15 Mn
Mar 31, 2025 -8.15 Mn
Dec 31, 2024 -5.90 Mn
Dec 31, 2024 -5.90 Mn